NEED HELP?


Name:
Phone
Email:
 


CURRICULUM VITAE
ANTON J. BILCHIK, M.D., Ph.D., FACS
 

Work Address: California Oncology Research Institute
2336 Santa Monica Boulevard #206
Santa Monica, California 90404
Tel: (310) 696-0716
Fax: (310) 696-0724
Email: abilchik@aol.com
Date of Birth: August 29, 1962
Citizen: U.S.A.
Marital Status: Married, 2 children
Present Position: Medical Director, California Oncology Research Institute
Clinical Professor, David Geffen School of Medicine at UCLA
Education:  
1980-1983 Undergraduate: University of Witwatersrand
1980-1985 Medical School: University of Witwatersrand
School of Medicine, Johannesburg, SA
1986 Rotating internship: Johannesburg General, Johannesburg
1987-1990 Ph.D./Postdoctoral Associate: GI Surgical Research Group:
Yale University School of Medicine, CT
1990-1991 Surgical Internship: University of California, Los Angeles
1992-1993 Surgical Research Fellow: University of California, Los Angeles
1991-1996 General Surgery Residency: University of California, Los Angeles
(M.J. Zinner)
1996 Chief Resident: University of California, Los Angeles, CA
1996-1997 Surgical Oncology Fellowship: John Wayne Cancer Institute (D.L. Morton)
Degrees:  
1985 MBBcH
1991 PhD                                                                             
Growth and secretory effects of cholecystokinin and its permissive role
in experimental pancreatitis.
Licensure:  
1987 United States FMGEMS/ECFMG No.3985454
1988 United States FLEX ID 620927500
1987 Britain No.3162691 (Registered with British Medical Council)
1987 South Africa No.IN 19467 S.A.M.D.C.
1991 California A49766
1991 DEA BB2950980
Board Certification:  
1996 Board certified General Surgery 052475
Academic Appointments:  
1996-Present Assistant Clinical Professor, UCLA School of Medicine
1997-2003 Assistant Director of Surgical Oncology, John Wayne Cancer Institute
2003-2007 Director Gastrointestinal Surgical Oncology, John Wayne Cancer Institute
2008-present Medical Director California Oncology Research Institute
Clinical Professor David Geffen School of Medicine at UCLA
Hospital Appointments:  
1996-Present Saint John’s Hospital and Health Center, Santa Monica, CA
1996-2004 Century City Medical Center, Los Angeles, CA
2004-Present Midway Hospital Medical Center, Los Angeles, CA
2004-Present Cedars-Sinai Medical Center, Los Angeles, CA
Professional Honors or Awards:  
1985 Black Belt 2nd Degree
1987 Gold Medal awarded at National University Championships
Appointed Karate Instructor Yale University
1988 First prize presentation, Connecticut Chapter, American College of Surgeons
1989 Black Belt 3rd Degree
1990 Winner Publication of the Year Surgical Research Communications
1992 Finalist American College of Surgeons, Research Fellowship
1992 Finalist Association Academic Surgeons, Research Fellowship
1996 Golden Apple Award “Outstanding Teacher”
UCLA General Surgery
1999 Vice Chair of Surgery, St. John’s Hospital
2000 Chief of Credential Committee, St. John’s Hospital
2000 Boerhaave Visiting Professor, University of Leiden
2001 America’s Top Doctor – Surgery
2001 Chief of Surgery, Century City Hospital
2002 Young Surgeon Representative American College of Surgeons
2002 America’s Top Doctor – Surgery
2003 America’s Top Doctor – Surgery
2004 America’s Top Doctor – Surgery
2005 America’s Top Doctor – Surgery
2007 Chief of Surgery Century City Hospital
Professional Organizations:  
1998 Member Society Surgical Oncology
1998 Member Longmire Surgical Society
1999 Member Bay Surgical Society
1999 Fellow American College of Surgeons
1999 Member American Society of Clinical Oncology
2000 2000 Member Society of American Gastrointestinal Endoscopic Surgeons
2000 Member American Gastroenterological Association
2000 Member Western Surgical Association
2000 Member Los Angeles Surgical Society
2000 Member Southern California Chapter American College of Surgeons
2002 Member Pacific Coast Surgical Society
2002 Local Program Chairman Society of Surgical Oncology
2004 Member Surgical Biology Club II
2006 Member of American Hepato Pancreato Biliary Association
2006 Program Committee Western Surgical Association
2007 Member of American Surgical Association
2008 Program committee American Hepatobiliary Association
Executive Councils:  
2003-2007 Western Surgical Association
2003-2007 Society of Surgical Oncology
Editorial Boards:  
2000 Ad hoc Reviewer Cancer
2001 Editorial Board, Annals of Surgical Oncology
2002 Editorial Board, Integrative Cancer Therapies
2002 Ad hoc Reviewer, Cancer
2003 Ad hoc Reviewer, Annals of Surgery
2004 Editorial Board, Journal of Clinical Oncology
2004 Editorial Board, Journal of Surgical Oncology
2004 Ad hoc Reviewer, Journal of American College of Surgeons
2004 Ad hoc Reviewer, Surgery
2006 Ad hoc Reviewer, European Journal of Surgical Oncology
2007 Ad hoc Reviewer, Gastroenterology and Hepatology
2007 Ad hoc Reviewer Diseases of Colon and Rectum
2007 Ad hoc Reviewer World Journal of Surgery
2008 Editorial Board, Journal of Interventional Oncology
NCI Grant Committees  
2007 Study Section “H” Review of Cancer Cooperative Groups and Grants
Clinical Areas of Special Interest:  
  Gastrointestinal and Laparoscopic Surgery
  Surgical Oncology
  Hepatic Malignancies
  Ultrastaging of Gastrointestinal Malignancies
Research Areas of Special Interest:  
  Physiology of circulating gastrointestinal regulatory peptides.
  Radioimmunoassay of peptides in pathophysiological conditions.
  Role of cholecystokinin in the control of growth and regulation of the pancreas.
  Pathophysiology of an endocrine tumor-peptic ulcer model.
  Oncogene expression and amplification in carcinoid tumors.
  Molecular and physiological regulation of small bowel absorption.
  Molecular profiling of gastrointestinal malignancies.
  Immunotherapy of gastrointestinal malignancies.
Research Grant Funding:  
1988-1989 Amelioration of traumatic pancreatitis by CCK antagonist.
OHSE research award-Yale University. $10,000, PI – AJ Bilchik M.D.
1989-1990 Bacterial and specific contribution to the mortality of post traumatic pancreatitis
in a guinea pig model.
OHSE research award-Yale University. $9,500, PI – AJ Bilchik M.D
1990-1991 Oncogene expression in mastomys carcinoid tumors.
OHSE research fund award-Yale University. $10,000, PI – AJ Bilchik M.D
1991-1997 Surgery and intestinal absorption.
NIH DK39870-05. (Co-investigator) $600,000, PI – MJ Zinner
1997 Early diagnosis and treatment of pancreatic cancer.
SPORE institutional grant (Collaborator)
1998 Molecular Detection of Colon Cancer with a Multiple Marker PCR Assay.
Rod Fasone Fund $10,000
1998-1999 Rogavin-Davidow Foundation $75,000
1998-1999 Polyvalent Vaccine: Phase III Trial in Stage IV Melanoma
NIH/NCI 5 P-01 CA29605-18  $878,746, PI – DL Morton M.D.
1998-1999 New Approaches to Surgical Oncology
NIH/NCI 5 P01 CA 29605-18  $2,218,374, PI – DL Morton M.D.
1999 Rod Fasone Fund $15,000
1999-2000 Rogavin-Davidow Foundation $75,000
1999-2000 Surgery, Immunology and Immunology of Human Cancer
NIH/NCI 5 P01 CA12582-28  $3,810,835, PI – DL Morton, M.D.
1999-2000 Unrestricted research grant - Rita Medical Incorporated  $50,000
2000 Rod Fasone Fund $10,000
2000-2003 Ultrastaging of Early Colon Cancer Using Lymphatic Mapping and Sentinel Node Analysis $150,000, PI - AJ Bilchik M.D. Ph.D.
2000-2003 Ultrastaging of Early Colon Cancer Using Lymphatic Mapping and Sentinel Node Analysis
NIH/NCI 1 R01 CA90848-01  $2,631,076, PI – AJ Bilchik M.D. Ph.D.
2000-2005 Lymph node mapping and sentinel lymph node biopsy for stage I, II, III colon
cancer.  American College of Surgeons Oncology Group Grant (submitted)
Collaborator / Co-Investigator - AJ Bilchik M.D. Ph.D.
2000-2001 Carbohydrate Antigens As Targets for Vaccine Immunotherapy in Colon Cancer NIH/NCI K08 Grant (submitted), PI – AJ Bilchik M.D. Ph.D.
2000-2001 Carbohydrate Antigens As Targets for Vaccine Immunotherapy in Colon Cancer American Cancer Society Beginning Investigators Grant (submitted), PI - AJ Bilchik M.D. Ph.D.
2000-2001 Rogavin-Davidow Foundation $75,000
2001 Polyvalent Vaccine: Phase III Trial in Stage IV Colon Cancer, PI – AJ Bilchik, M.D., Ph.D.
2001 Rod Fasone Fund $15,000
2001 George Hoag Foundation $35,000
2001-2002 Rogavin-Davidow Foundation $75,000
2002 SPORE in Pancreas Cancer, Co-Investigator – AJ Bilchik M.D. Ph.D., PI – T Adrian, Ph.D.
2002 William Randolph Hearst Foundation $500,000
2002-2003 Davidow Charitable Fund $75,000
2003-2004 Davidow Charitable Fund $75,000
2004-2005 Davidow Charitable Fund $75,000
2004-2006 Davidow Charitable Fund $75,000
2008-2012 Ultrastaging of Early Colon Cancer. NIH/NCI 2RO1 CA90848-05A2 $2,638,184.
PI – AJ Bilchik M.D.Ph.D. FUNDED
Original Publications:  
    1. Vellet D, Leiman G, Mair S, Bilchik AJ.  Fine needle aspiration cytology of mucinous cystadenocarcinoma of the pancreas: Further observations.  Acta Cytol 1988;32:43-48.
    2. Longo WE, Ballantyne GH, Vukasin AP, Bilchik AJ, Adrian TE, Modlin IM. Deoxycholic acid release of peptide YY from colonic endocrine cells: a specific and non neurally mediated mechanism.  Surg Forum 1988;39:182-183.
    3. Basson MD, Fielding LP, Bilchik AJ, Zucker KA, Ballantyne GH, Adrian TE, Modlin IM.  Does VIP mediate the pathophysiology of bowel obstruction? Am J Surg 1989;157:109-115.
    4. Longo WE, Ballantyne GH, Bilchik AJ, Modlin IM.  Advanced rectal cancer: What Is the Best Palliation? Dis Colon Rectum 1989;31(11):842-847.
    5. Zucker KA, Longo WE, Bilchik AJ, Adrian TE, Modlin IM.  Malignant diathesis from jejunal-ileal carcinoids.  Am J Gastroenterol 1989;84(2):182-186.
    6. Modlin IM, Bilchik AJ, Zucker KA, Adrian TE, Graham S, Sussman J.  Cholecystokinin augmentation of surgical pancreatitis: Benefits of receptor blockade.  Arch Surg 1989;124:574-578.
    7. Bilchik AJ, Modlin IM, Nilsson O, Zucker KA, Adrian TE. H2 receptor blockade induces peptide YY (PYY) and enteroglucagon (EG) secreting gastric carcinoids in mastomys.  Surgery 1989;106(6):1119-1127.
    8. Zucker KA, Bilchik AJ, Adrian TE, Modlin IM.  Postaglation E analogue inhibition of pancreatic enzyme secretion.  Pancreas 1989;4(6):708-714.
    9. Ballantyne GH, Longo WE, Adrian TE, Vukasin A, Bilchik AJ, Modlin IM. Deoxycholate stimulated release of peptide YY from isolated perfused rabbit colon: a specific and non-neurally mediated mechanism.  Am J Physiol 1989;257:G715-G724.
    10. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals. Am J Physiol 1989;257:G511-516.
    11. Savoca PE, Ballantyne GH, Adrian TE, Bilchik AJ, Modlin IM.  cAMP mediated release of PYY from the isolated perfused colon: Evidence for negative feedback modulation of colonic secretion.  Surg Forum 1989;40:177-180.
    12. Adrian TE, Zucker KA, Bilchik AJ, Modlin IM.  A novel micro-method for pancreatic acinar secretion: Time course of CCK stimulation and its inhibition by L364,718.  Int J Pancreatol 1990;6(1):61-69.
    13. Bilchik AJ, Zucker KA, Adrian TE, Sussman J, Modlin IM.  Cholecystokinin receptor blockade ameliorates pancreatitis in a new surgical model.  Surg Res Commun 1990;8(1):47-57.
    14. Bilchik AJ, Nilsson O, Modlin IM, Zucker KA, Adrian TE.  Significance of gastric endocrine tumor and age related gut peptide alterations in mastomys.  Regul Peptides 1990;27(2):195-207.
    15. Nillson O, Bilchik AJ, Adrian TE, Modlin IM.  Intraocular transplantation of carcinoid tumors from mastomys and humans.  J Pathol 1990;160(4):347-356.
    16. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM.  Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist.  Arch Surg 1990;125(12):1546-1549.
    17. Bilchik AJ, Ballantyne GH, Modlin IM.  Removal of malignant polyps is best done conservatively: A surgeon’s perspective.  Debates Med 1990; Volume 3.
    18. Modlin IM, Bilchik AJ, Goldenring JR.  Enterochromaffin-like cell tumor induction in mastomys by insurmountable H2 receptor blockade.  Res Clin Forums 1990;12:59-80.
    19. Bilchik AJ, Leach SD, Zucker KA, Adrian TE, Modlin IM.  Experimental models of acute pancreatitis.  J Surg Res 1990;48(6):639-647.
    20. Longo We, Ballantyne GH, Adrian TE, Bilchik AJ, Modlin IM.  Short chain fatty acid release of PYY in the isolated rabbit distal colon.  Scand J Gastroenterol 1991;26:4424-4448.
    21. Armstrong D, Ballantyne GH, Bilchik AJ, McMillen A, Adrian TE and Modlin IM.  Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction.  Dis Colon Rectum 1991;34(2):119-25.
    22. Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon.  Endocrinology 1991;129(1):139-148.
    23. Modlin IM, Kim H, Bilchik AJ, Nilsson O, Esterline WJ, Goldenring JR.  Pathobiology of enterochromaffin-like tumor induction in mastomys.  The stomach as an endocrine organ.  Eds. Hakanson R and Sundler F.  Elsevier 1991;33:499-513.
    24. Vukasin AP, Ballantyne GH, Nilsson O, Bilchik AJ, Adrian TE, Modlin IM.  Plasma and tissue alterations of peptide YY and enteroglucagon in rats after colectomy.  Yale J Biol Med 1992;65(1):1-15.
    25. Leach SD, Bilchik AJ, Karapetian O, Gorelick FS, Modlin IM.  Influence of choloroquine on diet-induced pancreatitis.  Pancreas 1993;8(1):64-69.
    26. Bilchik AJ, Hines OJ, Adrian TE, Skotzko MJ, McFadden DW, Zinner MJ, Ashley SW.  PYY gene expression is an early adaptive response to massive small bowel resection.  Surg Forum 1993;44:126-128.
    27. Adrian TE, Ballantyne GH, Longo WE, Bilchik, AJ, Graham S, Basson MD, Tierney RP and Modlin IM.  Deoxcholate is an important releaser of peptide YY and enteroglucagon from human colon.  Gut 1993;34:198-206.
    28. Hines OJ, Bilchik AJ, Skotzko MJ, Zinner MJ, McFadden DW, Ashley SW.  Translational control of meal-induced absorption.  Surg Forum 1993;44:133-134.
    29. Herrington MK, Permert J, Kazakoff KR, Pour PM, Zucker KA, Bilchik AJ, Adiran TE.  Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster.  Carinogenesis 1993;14(5):1021-1026.
    30. Ballantyne GH, Goldenring JR, Bilchik AJ, Adrian TE, Modlin IM.  cAMP-mediated release of peptide YY from the isolated perfused rabbit distal colon.  Regul Peptides 1993;47:117-126.
    31. Bilchik AJ, Hines OJ, Adrian TE, McFadden DW, Berger JJ, Zinner MJ, Ashley SW. Peptide YY is the physiological regulator of water and electrolyte absorption in the canine small bowel in vivo. Gastroenterology 1993;105:1441-1448.
    32. Modlin IM, Lewis JJ, Bilchik AJ, Kumar RR.  Management of unresectable malignant endocrine tumors of the pancreas.  Surg Gynecol Obstet 1993;176(5):507-518.
    33. Bilchik AJ, Hines OJ, Zinner MJ, Adrian TE, Bereger JJ, Ashley SW, McFadden DW.  Peptide YY augments postprandial small intestinal absorption in vivo. Am J Surgery 1994;167(6):570-574.
    34. Hines OJ, Bilchik AJ, Zinner MJ, Skotzko MJ, McFadden DW, Ashley SW.  Adaptation of the Na+/glucose cotransporter following intestinal resection.  J Surg Res 1994;57(1):22-27.
    35. Herrington MK, Permert J, Kazakoff KR, Zucker KA, Bilchik AJ, Pour PM, Adrian TE.  Effects of raw soya diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster.  Cancer Letters 1994;82:7-16.
    36. Hines OJ, Bilchik AJ, McFadden DW, Zinner MJ, Ashley SW.  Upregulation of the Na+/K+ ATPase following massive intestinal resection.  Surgery 1994;116(2):401-408.
    37. Bilchik AJ, Hines OJ, Adrian TE, Ashley SW, Zinner MJ, McFadden DW.  Peptide YY immunoneutralization inhibits meal induced absorption in vivo.  Surgery 1994;116:1153-1158.
    38. Hines OJ, Bilchik AJ, Ashley SW, Zinner MJ, McFadden DW.  Amino acids mediate postprandial jejunal postprandial absorption.  J Surg Res 1995;58:81-85.
    39. Bilchik AJ, Hines OJ, Adrian TE, Zinner MJ, McFadden DW, Ashley SW.  Early regional expression and secretion of peptide YY and enteroglucagon after massive small bowel resection.  J Am Coll of Surg 1995;180:417-426.
    40. Hines OJ, Bilchik AJ, Rodgers PJ, Berger J, Zinner MJ, Ashley SW.  Na+/H+ exchange regulates postprandial ileal water and electrolyte absorption.  Dig Dis Sci 1995;40:774-780.
    41. Liu CD, Aloia T, Adrian TE, Bilchik AJ, Ashley SW, Zinner MJ, McFadden DW.  Peptide YY; a potential proabsorptive hormone for the treatment of malabsorptive disorders.  Am Surg 1996;62(3):232-236.
    42. Whang EE, Hines OJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW.  Antisecretory mechanisms of peptide YY in rat distal colon.  Dig Dis Sci 1997;42(6):1121-1127.
    43. Bilchik AJ, Sarantou T, Wardlow J, Ramming K.  Cryosurgery causes a profound reduction in tumor markers in hepatoma and non-colorectal hepatic metastases.  Am Surg 1997;63: 796-800.
    44. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano A, Ramming KP.  Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy.  Surgery 1997;122:1040-1048.
    45. Sarantou T, Bilchik AJ, Ramming KP.  Complications of hepatic cryosurgery.  Semin Surg Oncol 1998;14:156-162.
    46. Bilchik AJ.  Editorial Cryotherapy of liver tumors.  Oncology July 1998.
    47. Bilchik AJ, Giuliano AE, Essner R, Bostick PJ, Kelemen P, Foshag LJ, Sostrin S, Turner RR, Morton DL.  Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms.  Cancer J Sci Am 1998;4(6):351-358.
    48. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik AJ, Giuliano AE.  Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?  Ann Surg 1999;229:536-541.
    49. Rose DM, Allegra DP, Bostick PJ, Foshag LJ, Bilchik AJ.  Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies.  Am Surg 1999;65:1009-1014.
    50. Bilchik AJ, Rose DM, Bostick PJ, Chu K, Allegra D, Morton DL.  Radiofrequency ablation – a minimally invasive technique with multiple applications.  Cancer J Sci Am 1999;5(6):356-361.
    51. Bilchik AJ, Rose DM, Hsueh E, Foshag LJ, Morton DL.  Cryosurgery and radiofrequency ablation of unresectable hepatic malignancies: A proposed algorithm.  Arch Surg 2000;135(6):657-664.
    52. Hines OJ, Whang EE, Bilchik AJ, Zinner MJ, Welton M, Lane J, McFadden DE, Ashley SW.  Role of Na+/-glucose co-transport in jejunal meal-induced absorption. Dig Dis Sci 2000;45:1-6.
    53. Bilchik AJ, Miyashiro M, Kelley M, Kuo C, Fujiwara Y, Nakamori S, Monden M, Hoon DSB.  Molecular detection of metastatic pancreatic carcinoma cells using a multimarker RT-PCR assay. Cancer 2000;88:1037-1044.
    54. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WY, Soh D, Bilchik AJ, Katopodis N, Morton DL.  Gangliosides as targets for immunotherapy of pancreatic adenocarcinoma. Cancer 2000;88:1828-1836.
    55. Habal N, Gupta R, Bilchik AJ, Johnson T, Morton DL.  TA90 – IC, a new marker for advanced colon cancer.  Ann Surg Oncol 2000;7:352-356.
    56. Tsioulias GT, Wood TF, Morton DL, Bilchik AJ.  Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms.  Arch Surg 2000;135(8):926-932.
    57. Wood TF, Rose DM, Allegra DP, Foshag LJ, Bilchik AJ.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.  Ann Surg Oncol 2000;7(8): 593-600.
    58. Ravindranath MH, Shen P, Habal N, Soh D, Nishimoto K, Gonzalez A, Tam WY, Bilchik AJ, Morton DL.  Does human melanoma express carcinoembryonic antigen?  Anticancer Res 2000;20(5A): 3083-3092.
    59. Wood TF, Tsioulias GJ, Rangel D, Hutchinson W, Foshag LJ, Morton DL, Bilchik AJ.  Focused examination of sentinel lymph nodes upstages early colorectal carcinoma.  Am Surg 2000;66(11):998-1003.
    60. Habal N, Sims C, Bilchik AJ.  Gastrointestinal carcinoid tumors and second primary malignancies.  J Surg Oncol 2000;75:306-310.
    61. Bilchik AJ, Tsioulias GJ, Wood TF, Morton DL.  Lymphatic mapping and sentinel lymphadenectomy: a novel technique to improve staging in patients with gastrointestinal neoplasms.  In ASCO 2001 Education Book, edited by Perry MC.  American Society for Clinical Oncology, Alexandria, VA, 2001, pp535-540.
    62. Bilchik AJ, Wood TF, Chawla SP, Rose DM, Chung MH, Stern SS, Foshag LJ, Ramming KP. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.  Clin Colorectal Cancer 2001;1(1):36-42.
    63. Bilchik AJ, Wood TF, Chung MH, Rose DM. Laparoscopic radiofrequency ablation of hepatic malignancies. In Surgical Laparoscopy, 2nd edition, edited by Zucker KA. Lippincott, Williams & Wilkins, 2001, pp 221-225.
    64. Chung MH, Foshag LJ, Bilchik AJ. Management of incidental gallbladder carcinoma following laparoscopic cholecystectomy. Contemp Surg 2001;57:506-511.
    65. Wood TF, Bilchik AJ. Radiofrequency thermal ablation as treatment for liver cancer at the John Wayne Cancer Institute. Oncology Issues 2001;16:17-20.
    66. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 2001;6:24-33.
    67. Bilchik AJ, Saha S, Stonecypher JA, Wood TF, Sostrin S, Turner RR, Wang H, Morton DL, Hoon DSB.  Molecular staging of early colon cancer based on sentinel node analysis: A multicenter phase II trial.  J Clin Oncol 2001;19:1128-1136.
    68. Miyashiro I, Kuo C, Huynh K, Iida A, Morton DL, Bilchik AJ, Giuliano A, Hoon DSB.  Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes.  Clin Chem 2001;47:505-512.
    69. Wood TF, Saha S, Morton DL, Tsioulias GJ, Rangel D, Hutchinson W, Foshag LJ, Bilchik AJ.  Validation of lymphatic mapping in colorectal cancer: in-vivo, ex-vivo, and laparoscopic techniques. Ann Surg Oncol 2001;8:150-157.
    70. Ravindranath MH, Gonzales A, Soh D, Nishimoto K, Tam WY, Bilchik A, Morton DL, O’Day S. Interleukin-2 binds to ganglioside GD(1b).  Biochem Biophys Res Commun 2001;283:369-373.
    71. Chung MH, Ye W, Ramming KP, Bilchik AJ. Repeat hepatic cryotherapy for metastatic colorectal cancer.  J Gastrointest Surg 2001;5:287-293.
    72. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, DDM, Ye W, Elashoff RM. Morton DL.  CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001;8:389-401.
    73. Tsioulias GJ, Wood TF, Morton DL, Bilchik AJ.  Diagnostic laparoscopy and laparoscopic ultrasonography optimize staging and resectability of intraabdominal tumors. Surg Endosc 2001;15:1016-1019.
    74. Chung MH, Wood TF, Tsioulias GJ, Rose DM, Bilchik AJ. Laparoscopic radiofrequency ablation of unresectable hepatic malignancies: a phase II trial. Surg Endosc 2001;15:1020-1026.
    75. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience.  Arch Surg 2001;136:950-955.
    76. Wood TF, Spirt M, Rangel D, Shen P, Tsioulias GJ, Morton DL, Bilchik AJ.  Lymphatic mapping improves staging during laparoscopic colectomy for cancer.  Surg Endosc 2001;15:715-719.
    77. Bilchik AJ, Saha S, Tsioulias GJ, Wood TF, Morton DL.  Aberrant drainage and missed micrometastases: the value of lymphatic mapping and focused analysis of sentinel lymph nodes in gastrointestinal neoplasms.  Ann Surg Oncol 2001;8(9S):82S-85S.
    78. Saha S, Bilchik A, Wiese D, Espinosa M, Badin J, Ganatra BK, Desai D, Kaushal S, Singh T, Arora M. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique - a multicenter trial.  Ann Surg Oncol 2001;8(9S):94S-98S.
    79. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ. Hepatic cytoreduction followed by a novel long-acting somatostatin analogue: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130:954-962.
    80. Yoon DY, Hines OJ, Bilchik AJ, Lewin K, Cortina G, Reber HA.  Solid and papillary epithelial neoplasms of the pancreas: Aggressive resection for cure.  Am Surg 2001;67:1195-1199.
    81. Taback B, Nakayama T, Wiese D, Turner R, Bilchik AJ, Saha S, Hoon D.  Detection of colorectal micrometastases in sentinel lymph nodes using the novel approach of PCR PNA clamping.  Proc Am Assoc Cancer Res 2001;42:612.
    82. Perez CA, Ravindranath MH, Gupta RK, Wood TF, van de Velde CJ, Tollenar RA, Soh D, Morton DL, Bilchik AJ. Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer. Cancer J, 2002;8:55-61.
    83. Litvak DA, Wood TF, Tsioulias GJ, Chung M, Chawla SP, Foshag LJ, Morton DL, Ramming KP, Bilchik AJ.  Systemic irinotecan and regional floxuridine following hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.  Ann Surg Onc 2002;9:148-155.
    84. Saha S, Bilchik AJ, Wiese D.  Sentinel lymph-node mapping in colorectal cancer.  In Colorectal Cancer: A Clinical Guide to Therapy, edited by Bleiberg H, Kemeny N, Rougier P, Wilke H. 
    85. Chung MH, Gupta RK, Bilchik AJ, Ye W, Yee R, Morton DL. Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study.  Current Surg 2002;59:194-8.
    86. Bilchik AJ, Nora D, Tollenaar RAEM, van de Velde CJH, Wood T, Turner R, Morton DL, Hoon DSB.  Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis.  Eur J Ca 2002;38:977-85.
    87. Wood TF, Nora DT, Morton DL, Turner RR, Rangel D, Hutchinson W, Bilchik AJ.  One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: Detection of missed micrometastases. J Gastrointest Surg 2002;6:322-30.
    88. Bilchik AJ, Nora DT. Lymphatic mapping of nodal micrometastasis in colon cancer: Putting the cart before the horse?  Ann Surg Onc 2002;9:529-31.
    89. Tsioulias GJ, Wood TF, Spirt M, Morton DL, Bilchik AJ. A novel lymphatic mapping technique to improve localization and staging of early colon cancer during laparoscopic colectomy. Am Surg 2002;68:561-5.
    90. Morton DL, Hsueh EC, Essner R, Foshag LJ, O’Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM.  Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.  Am Surg 2002;236:438-49.
    91. Ravindranath MH, Wood TF, Soh D, Gonzales A, Muthugounder S, Perez C, Morton DL, Bilchik AJ.  Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM.  Cryobiology 2002;45:10-21.
    92. Bilchik AJ, Nora DT, Saha S, Turner RR, Wiese D, Kuo C, Ye X, Morton DL, Hoon DS.  Molecular profiling of early colon cancer predicts micrometastases.  Arch Surg 2002;137:1377-1383.
    93. Bleicher RJ, Bilchik AJ.  Radiofrequency ablation in 447 complex unresectable liver tumors: Lessons learned.  Ann Surg Onc 2002;10:52-58.
    94. Litvak DA, Bilchik AJ, Cabot MC.  Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy.  J Gastrointest Surg 2003;7:140-148.
    95. Bilchik AJ, Nora DT, Sobin LH, Turner RR, Trocha SD, Krasne D, Morton DL, Bilchik AJ.  Effect of lymphatic mapping on the new Tumor-Node-Metastasis classification for colorectal cancer.  J Clin Onc 2003;21:668-672.
    96. Trocha S, Nora DT, Saha SS, Morton DL, Trocha SD, Wiese D, Bilchik AJ.  Combination probe and dye-directed lymphatic mapping detects micrometastases in early colorectal cancer. J Gastrointest Surg 2003;7:340-346.
    97. Bilchik AJ.  More (nodes) + more (analysis) = less (mortality): Challenging the therapeutic equation for early-stage colon cancer.  Ann Surg Oncol 2003; 10:203-205.
    98. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang H, Hoon DSB.  Quantitative c-MET mRNA expression in primary colon cancer: A predictor of tumor invasion and lymph node metastases.  Clin Cancer Res 2003;9:1480-1488.
    99. Bilchik AJ.  Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: An update.  Surg Onc Clin North Amer 2003;12:193-210.
    100. Yao K, Bilchik A.  Local excision of a small squamous cell carcinoma of the anal canal: Case report and review of the literature.  Contemp Surg, 2003;59:126-131.
    101. Curley SA, Bilchik AJ, Fraker DL, McMasters KM.  Symposium: Radiofrequency ablation of hepatic malignancies.  Contemp Surg, 2003;59:162-172.
    102. Litvak D, Bleicher RJ, Bilchik AJ.  RFA of a refractory unresectable insulinoma of the pancreas.  Contemp Surg 2003;59:229-232.
    103. Turner RR, Nora DT, Trocha SD, Bilchik AJ.  Colorectal carcinoma nodal staging.  Frequency and nature of cytokeratin-positive cells in sentinel and non-sentinel lymph nodes. Arch Path Lab Med 2003;127:673-679.
    104. Bleicher RJ, Bilchik AJ.  Complications of hepatic RFA: Lessons learned.  In Radiofrequency Ablation of Cancer: Current Indications, Techniques, and Outcomes, edited by Ellis LM, Curley SA, Tanabe KK.  Springer-Verlag, New York, 2003, pp 121-134.
    105. Bilchik AJ.  Thermal ablation of hepatic colorectal metastasis: should this minimally invasive technique replace resection?  In ASCO 2003 Education Book, edited by Perry MC.  American Society for Clinical Oncology, Alexandria, VA, 2003, pp 699-710.
    106. Morton DL., Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, Bilchik AJ, Elashoff D, Elashoff R.  Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.  Ann Surg 2003;238:538-550.
    107. Bilchik AJ, Trocha SD.  Lymphatic mapping and sentinel node analysis to optimize laparoscopic resection and staging of colorectal cancer: An update.  Cancer Control 2003;10:219-223.
    108. Trocha SD, Saha SS, Wiese D, Thompson J, Morton DL, Bilchik AJ.  Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: Impact on adjuvant treatment.  Am Surg 2003;69:918-922.
    109. Bilchik AJ, Faries M.  Radiofrequency ablation of hepatic malignancies: Inexpensive and minimally invasive, but should it replace resection?  Ann Surg Oncol 2003;10:1002-1004.
    110. Bilchik AJ, Essner R, Thompson JF, Morton DL.  Hepatic surgery for metastatic melanoma.  In Textbook of Melanoma: Pathology, Diagnosis and Management, edited by Thompson JF, Morton DL, Kroon BBR.  Martin Dunitz Publishers, London, 2004, pp 505-513.
    111. Taback B, Bilchik AJ, Saha S, Nakayama T, Wiese DA, Turner RR, Kuo CT, Hoon DSB.  Peptide nucleic acid clamp PCR: A novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 2004; 111: 409-414.
    112. Bilchik AJ, Martinez S. Novel effective drugs and evolving ablation technology: A more comprehensive approach to hepatic malignancies. Ann Surg Oncol 2004; 11: 458-459.
    113. Saha S, Dan AG, Bilchik AJ, Kitagawa Y, Schochet E, Choudri S, Saha L,  Wiese D, Morton D, Kitajima M.  Historical review of lymphatic mapping in gastrointestinal malignancies.  Ann Surg Oncol 2004; 11: 245S-249S.
    114. Umetani N, Fujimoto A, Takeuchi H, Shinozaki M, Bilchik AJ, Hoon DS.  Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colon carcinoma.  Oncogene 2004; 23(50): 8292-300.
    115. Dan A, Saha S, Wiese D, Bilchik AJ, Nolff M, Beutler T, AlSamkari R, Barber K, Branigan T, Kaushal S.  Upstaging of early colon cancer (T1 & T2) by sentinel lymph node (SLN) mapping.  Ann Surg Oncol 2004;11(2):S109-S110.
    116. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS.  Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004; 10:7475-7483.
    117. Martinez SR, Bilchik AJ. Quality control issues in the management of colon cancer patients. Eur J Surg Onc, 2005; 31: 616-629.
    118. Martinez S, Bilchik AJ. Lymphatic mapping and sentinel node analysis in colon cancer: A review. Clinical Colorectal Cancer, 2005; 4: 320-324.
    119. Kim J, Takeuchi H, Lam ST, Turner RR, Wang H-J, Kuo C, Foshag L, Bilchik AJ, Hoon DSB. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23:2744-2753.
    120. Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, Bilchik AJ, Turner R, Tran A, Kuo C, Hoon DS.  X-linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-Met pathway via AKt signaling.  Clin Cancer Res 2005; 11:7621-7628.
    121. Bilchik AJ, Poston G, Curley SA. Strasberg S, Saltz L, Adam R, Nordlinger B, Rosen LS, Rougier P.  Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005; 23:9073-9078. .
    122. Martinez SR, Young SE, Giuliano AE, Bilchik AJ.  The utility of estrogen receptor, progesterone receptor and HER-2/neu status to predict survival in patients undergoing resection for breast cancer metastases.  Am J Surg 2006; 191:281-283.
    123. Saha S, Seghal R, Patel M, Doan K, Dan A, Bilchik A, Beutler T, Wiese D, Bassily N, Yee C. A multicenter trial of sentinel lymph node mapping in colorectal cancer:prognostic implications for nodal staging and recurrence. Am J Surg 2006; 19:305-310
    124. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DSB. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006;244:113-120
    125. Chen, SL, Iddings DM, Schrei RP, Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin 2006;56:292-309
    126. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving respectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-80
    127. Zogakis TG, Bilchik AJ.  Radiofrequency thermal ablation of liver tumors. In Textbook Surgery of the Liver, Biliary Tract and Pancreas, 4th Edition, edited by Blumgart LS, Belghiti J.  Elsevier, Philadelphia, PA, October 2006
    128. Kim J, Takuji M, Amersi F, Martinez S, Kuo C, Turner RR, Yi C, Bilchik AJ, Morton DL, Hoon DSB. Chemokine receptor CXCR4 expression by melanoma and colorectal cancer facilitates liver metastasis and correlates with disease outcome. Ann Surg Oncol, 2006; 244(1) 113-120.
    129. Martinez SR, Young SE, Hoedema R, Foshag LJ, Bilchik AJ.  Colorectal cancer screening and surveillance: Current standards and future trends.  Ann Surg Oncol 2006; 13(6):768-775.
    130. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X, Amersi FF, Martinez SR, Dry SM, Bilchik AJ, Hoon DSB.  The clinical significance of MAGE-3 expression in pancreatic cancer.  Int J Cancer, 2006; 118(9) 2269-2275.
    131. Bilchik AJ.  Novel Insights into the Diagnosis and Treatment of Melanoma. In Melanoma- Surgical Oncology Clinics of North America, edited by Petrelli N, Bilchik AJ, Elsevier, Philadelphia, PA, 2006; 240pgs
    132. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ.  Long Term Survival after Radiofrequency Ablation of Complex Unresectable Liver Tumors.  Arch Surg, 2006;141(6):581-588
    133. Bilchik AJ, DiNome M, Saha S, Turner R, Wiese D, McCarter M, Hoon DSB, Morton DL.  Prospective multicenter trial of staging adequacy in colon cancer: preliminary results.  Arch Surg, 2006;141(6):527-534
    134. Martinez S, Chen S, Bilchik AJ.  Treatment disparities in Hispanic rectal cancer patients: a SEER database study.  Am J Surg 2006;72:906-908
    135. Aikou T, Kitagawa Y, Kitajima M, Uenosono Y, Martinez SR, Bilchik AJ, Saha S.  Sentinel Lymph Node Mapping for GI Cancer.  Cancer Metastasis Reviews (supplemental issue), 2006; 25(2):269-277.
    136. Umetani N, Kim J, Hiramatsu S, Bilchik AJ, Reber HA, Hines OJ, Hoon DS.  Elevated integrity of free circulating DNA in sera of colorectal and periampullary cancer patients:  A direct quantitative PCR for ALU repeats.  Clin Chem, 2006;52(6) 1062-1069.
    137. Kim J, Reber HA, Dry SM, Elashoff D, Chen S, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu S, Bilchik AJ, Yong S, Shoup M, Hoon D.  Unfavorable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.  Gut, May 2006;55:1598-1605.
    138. Iddings DM, Ahmad A, Elashoff D, Bilchik AJ. The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-analysis. Ann Surg Oncol, 2006;13:1386-1392
    139. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006;244:602-610
    140. Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg. 2006;72(10):875-9
    141. Bilchik AJ. Colorectal cancer metastatic to the liver: radiofrequency ablation. In Current Surgical Therapy, edited by Cameron JL. Ninth edition. Elsevier, Philadelphia, 2007
    142. Bilchik AJ. Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach. Hematol Oncol Clin, North Am 2007;21(Suppl 1):8-18
    143. Bilchk, AJ. Summary on “More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study”. NEJM, 2007
    144. Kavanagh MA, Ahmad A, Amadpour M, Bilchik AJ. Image of the month: serrated adenomatous polyposis. Arch Surg 2007; 142(9):902
    145. Nicholl MB, Bilchik AJ. Radiofrequency ablation of colorectal carcinoma liver metastases Current Colorectal Cancer Reports. Volume 3: Issue 2, April 2007;3: 99-103
    146. Iddings DM, Koda EA, Gewel SS, Parker R, Saha D, Bilchik AJ. Angiogenesis markers in early
    147. Chen SL, Bilchik AJ. Resecting lymph nodes in colon cancer: more than a staging operation? 
    148. Iddings DM, Bilchik AJ. Gastric Carcinoma: Applying the sentinel node paradigm to improve the 
    149. Bilchik, AJ, Compton C. Close collaboration between surgeon and pathologist is essential for
    150. Ahmad A, Chen SL, Bilchik, AJ. Role of repeated hepatectomy in the multimodal treatment of
    151. Wright BE, Lee C, Bilchik AJ. Hepatic cytoreductive surgery for neuroendocrine cancer. Surg
    152. Iddings D, Bilchik AJ. The biologic significance of micrometastatic disease and sentinel lymph
    153. Wright BE, Bilchik AJ. Management of T2 Gallbaladder Cancer: Are practice patterns consistent
    154. Bilchik AJ, Hoon DSB, Saha S, Weise D, DiNome M, Turner R, Koyanga K, McCarter M, Shen
    155. Rosen L, Bilchik AJ, Beart RW, Benson AB, Chang KJ, Compton CC, Grothey A, Haller DH, Ko CY, Lynch PM, Nelson H, Stamos M, Turner R, Willett CG. New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer. Clin Cancer Research 2007;13:6853-6.
    156. de Maat MF, Van de Velde C, Umetani N, de Heer P, Putter H, Van Hoesel A, Meijer GA, Van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar R, Hoon DS. Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. J Clin Oncol 2007; 25:4887-4894
    157.  Bilchik AJ. Current and Emerging Strategies for the Treatment of Unresectable Hepatic
    158. 158. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer (commentary)? Ann Surg Oncol, 2008:15(1);1-3.
    159. Iddings DM, Wright BE, Bilchik AJ. A rare cause of primary hepatic neoplasm: malignant peripheral nerve sheath tumor (MPNST) in the age of modern liver surgery. Am Surg, 2008; 74:47-50.
    160. Nicholl, M, Bilchik AJ. Thermal Ablation of Hepatic Malignancy: Useful But Still Not Optimal. Eur J Surg Oncol, 2008; 34:318-23.
    161. Koyanagi K, Bilchik AJ, Saha S, Turner RR, et al. Clinical relevance of occult nodal micrometastases and circulating tumor cells in early colorectal cancer in a prospective multicenter trial.  Clin Cancer Research 2008; 22:7391-7396.
    162. deMaat M, van de Velde C, van der Werff M, Putter H, Umetani N, Klein-Kranenbarg E, Turner R, van Krieken J, Bilchik AJ, Tollenaar R, Hoon D. Quantitative Analysis of Methylation of Genomic Loci in Early Stage Rectal Cancer Predicts distant Recurrence. J Clin Oncol 2008; 26:2327-35.
    163. Bilchik AJ, Hecht JR. Perioperative Risks of Bevacizumab and other Biological Agents for Hepatectomy: Theoretical or Evidence Based? J Clin Oncol 2008; 26:1786-9.
    164. Wasif N, Faries M, Saha S, Turner R, Wiese D, McCarter M, Shen P, Bilchik AJ. Primary colorectal tumor characteristics as predictors of occult nodal metastasis in a prospective multicenter trial. Submitted Archives of Surgery 2008.
    165. Wasif N, Sasu S, Conway W, Bilchik AJ. Focal Nodular Hyperplasia (FNH): Report of an Unusual Case and Review of the Literature. Am Surg 2008; 74:1100-1103.
    166. Graeme J Poston, Joan Figueras, Felice Giuliante ,Gennaro Nuzzo, Alberto F Sobrero, Jean-Francois Gigot, Bernard Nordlinger, Rene Adam, Thomas Gruenberger, Michael A Choti, Anton J Bilchik,  Eric Van Cutsem, Michael I D’Angelica. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 29:4828-4833.
    167. Telian SH, Bilchik AJ. Significance of the Lymph Node Ratio in Stage III Colon Cancer. Ann Surg Oncol 2008; 6:1557-1558.
    168. Stojadinovich A, Nissan A, Protic M, Bilchik AJ, Peoples G. Targeted Nodal Assessment in Colon Cancer. Ann Surg 2008; 5:902-904.
    169. Bilchik AJ, Poston G, Adam R, Choti M. Prognostic Variables for Colorectal Cancer Hepatic Metastases: An Evolving Paradigm! J Clin Oncol 2008; 26:5320-5321.
    170. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer? Ann Surg Oncol 2008; 1:1-3.
    171. Bilchik AJ, Stojadinovic A, Wainberg Z, Hecht JR. Targeted lymph node evaluation in colorectal cancer: a decade of progress! J Surg Oncol 2009 5:273-274.
    172. Cahill RA, Bembenek A, Sirop S, Waterhouse DF, Schneider W, Leroy J, Wiese D, Beutler T, Bilchik A, Saha, S, Schlag PM. Sentinel node biopsy for individualization of surgical strategy for cure of early-stage colon cancer, May 27, 2009.
Published Abstracts:
    1. Adrian T, Zucker KA, Bilchik AJ, Modlin IM.  Cholecystokin receptor antagonist blocks diet-induced pancreatic hypertrophy in the hamster.  Clin Res 1987;35(5):796A.
    2. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM.  Amelioration of traumatic pancreatitis by a new specific CCK receptor antagonist.  Gastroenterology 1988;94:A35.
    3. Adrian TE, Bilchik AJ, Zucker KA, Modlin IM.  Cholecystokinin receptor antagonist blocks fat induced pancreatic growth but increases food intake and body weight in the hamster.  Gastroenterology 1988;94:A3.
    4. Longo WE, Ballantyne GH, Vukasin AP, Bilchik AJ, Adrian TE, Modlin IM.  Bile salts release peptide tyrosine tyrosine.  Gastroenterology 1988;94:A269.
    5. Bilchik AJ, Fielding LP, Basson MD, Zucker KA, Ballantyne GH, Adrian TE, Modlin IM.  Postpransial portosystemic differences in secretion and somatostatin release in the dog.  Gastroenterology 1988;94:A34.
    6. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM.  Is cholecystokinin responsible for normal pancreatic growth?  Gastoenterology 1988;94:A518.
    7. Adrian TE, Bilchik AJ, Zucker KA, Modlin IM.  CCK receptor blockade increases hamster body weight and food intake.  FASEB Journal 1988;2(4):A737.
    8. Bilchik AJ, Zucker KA, Sussman J, Adrian TE, Modlin IM.  New specific CCK receptor antagonist ameliorates surgically induced pancreatitis both pre and post insult.  Br J Surg 1988.
    9. Bilchik AJ, Nilsson O, Modlin IM, Zucker KA and Adian TE.  Rapid carcinoid tumor induction in mastomys with H2 receptor blockade.  Connecticut Med 1988.
    10. Armstrong DN, Bilchik AJ, Adrian TE, Zucker KA, Modlin IM.  PYY and enteroglucagon levels are elevated after proctocolectomy and pelvic ileal-anal anastomosis.  Gastroenterology 1989;96:A15.
    11. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM.  Parenteral, but not oral L369,718 ameliorates acute experimental pancreatitis.  Gastroenterology 1989;96;A45.
    12. Zucker KA, Bilchik AJ, Leach SD, Adrian TE, Modlin IM.  Continuous cholecystokinin receptor blockade in newborn guinea pigs: impaired growth and altered secretagogue response.  Gastroenterology 1989;96;A568.
    13. Nillson O, Bilchik AJ, Adrian TE, Modlin IM.  Gastric carcinoids of praomys natalensis contain PYY and enteroglucagon like immunoreactivity.  Gastroenterology 1989;96;A366.
    14. Savoca PE, Ballantyne GH, Adrian TE, Bilchik AJ, Pernikoff B, Modlin IM.  Xylocaine does not inhibit deoxycholate stimulated PYY release.  Gastroenterology 1989;96;A444.
    15. Vukasin AP, Ballantyne GH, Adrian TE, Bilchik AJ, Pernikoff B, Modlin IM.  Elevations in plasma and tissue PYY after colectomy.  Gastroenterology 1989;96.
    16. Modlin IM, Bilchik AJ, Kacinski B, Esterline W, Goldenring JR.  Oncogene amplification in gastric carcinoid tumors induced by acid secretory blockade in mastomys.  Gastroenterology 1990.
    17. Bilchik AJ, Hines OJ, Zinner MJ, Adrian TE, McFadden DW, Ashley SW.  Physiological significance of PPY in small intestinal absorption in vivo.  Gastroenterology 1993;623:A157.
    18. Bilchik AJ, Hines OJ, Zinner MJ, Berger JJ, McFadden DW, Adiran TE, Ashley SW.  PYY augments postprandial small intestinal absorption in vivo.  Gastroenterology 1993;506:A127.
    19. Hines OJ, Bilchik AJ, Rodgers PJ, Berger J, Zinner MJ, Ashley SW.  Na+/H+ exchange regulates postprandial ileal absorption.  Gastroenterology 1993;611:A153.
    20. Kelley MC, Bostick P, Bilchik AJ, Foshag LJ, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB.  Molecular detection of pancreatic carcinoma (PC) with a multiple marker RT-PCR assay.  Proc Am Soc Clin Oncol 1997;16:293a.
    21. Sarantou T, Bilchik AJ, Ramming K.  Cryoablation of primary and metastatic liver cancer unresponsive to conventional therapy.  Proc Am Soc Clin Oncol 1997;16:304a.
    22. Bilchik AJ, Ravindranath MH, Chu KU, Soh D, Morton DL.  Polyvalent vaccine includes an immune response to carbohydrate antigens in stage IV colon cancer.  Proc Am Soc Clin Onc 1999;18:455a.
    23. Bilchik AJ, Chawla S, Rose DM, Stern S, Ramming KP.  Systemic irinotecan (CPT-11) and regional chemotherapy prolong survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil (5-FU). .  Proc Am Soc Clin Onc 1999;18:254a.
    24. Chu KU, Ravindranath MH, Nishimoto K, Bilchik AJ, Morton DL.  Cell-surface expression of an immunogenic ganglioside (GM2) in pancreatic adenocarcinoma.  Proc Am Assoc Cancer Res 1999;40:470a.
    25. Ravindranath MH, Bilchik AJ, Chu K, Soh D, Shen P, Morton DL. Anti-GM2 IgM inversely correlates with the serum ganglioside level in colon cancer patients after vaccine therapy.  Proc Am Assoc Cancer Res 1999;40:577a.
    26. Bilchik AJ, Saha S, Stonecypher JA, Wood TF, Hoon DS.  Molecular staging of early colon cancer: lymphatic mapping and sentinel node analysis for occult micrometastasis.  Proc Am Soc Clin Oncol 2000;19:248a.
    27. Saha S, Bilchik AJ, Wiese D, Nora D, Badin J, Espinosa M, Ganatra BK, Seoane S, Gomez E, Singh T, Arora M.  Phase II study for upstaging of colorectal cancer (CRCA) by sentinel lymph node mapping (SLNM) technique - a multicenter trial.  Proc Am Soc Clin Oncol 2000;19:239a.
    28. Bilchik AJ, Ravindranath M, Gupta R, Habal N, Wood TF, Tsioulias GJ, Morton DL. CancerVax, a polyvalent vaccine improves survival in refractory stage IV colon cancer: a phase II trial. Proc Am Soc Clin Oncol 2001;20:252a.
    29. Ravindranath MH, Wood TF, Soh D, Perez C, Gonzales AM, Morton DL, Bilchik AJ.  Necrosis induced by cryotherapy of liver metastases increases serum ganglioside levels and provides an intrinsic adjuvant to augment specific IgM to tumor-associated gangliosides.  Proc Am Assoc Cancer Res 2001;42:507a.
    30. Saha S, Bilchik A, Espinosa M, Monson K, Nadimpalli R, Wiese D, Ganatra K, Desai D, Kaushal S, Nagaraju M.  Results of a multi-institutional trial of sentinel lymph node mapping (SLNM) in colorectal cancer (CRCa).  Proc Am Soc Clin Oncol 2001;584.
    31. Taback B, Nakayama T, Wiese D, Turner R, Bilchik A, Saha S, Hoon D. Detection of colorectal micrometastasis in sentinel lymph nodes using the novel approach of PCR PNA clamping. Proc Am Assoc Cancer Res 2001;42:612a.
    32. Bilchik AJ, Perez CA, Tollenar W, Morton DL, van de Velde CJ.  Multivariate analysis of 18 prognostic factors in early colon cancer: a prospective, multi-center trial.  Proc Am Soc Clin Oncol 2002;21:172a.
    33. Nora DT, Kadison AS, Trocha S, Riley C, Bilchik AJ, Morton DL.  Does nodal micrometastasis alter the staging and management of early stage colorectal cancer?  Proc Am Soc Clin Oncol 2002;21:117b.
    34. Takeunchi H, Bilchik A, Saha S, Wiese D, Kuo C, Ye X, Hoon DSB.  C-Met gene expression in primary colorectal cancer correlates with depth of tumor invasion and metastatic potential.  Proc Am Assoc Cancer Res 2002;43:217.
    35. Litvak, DA, Bilchik AJ, Cabot MC.  Modulators of ceramide metabolism enhance irinotecan-mediated apoptosis of colon cancer cells by a p53-independent process.  Ann Surg Oncol 2002;9(1):S10-S11.
    36. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ.  Radiofrequency ablation in 406 complex unresectable liver tumors: Lessons learned.  Ann Surg Oncol 2002;9(1):S8.
    37. Yao K, Nora D, Ye X, Morton D, Bilchik A.  Micrometastases in colon cancer: Perception versus reality.  Ann Surg Oncol 2003;10(1):S62.
    38. Kim J, Takeuchi H, Foshag L, Bilchik A, Hoon DSB.  Colorectal cancer expression of chemokine receptor CXCR4 promotes liver metastasis.  Proc Am Soc Clin Oncol 2004; 23:266.
    39. Kim J, Mori T, Lam S, Nguyen L, Morton D, Bilchik AJ, Hoon DSB.  CXCR4 chemokine receptor mediates melanoma and colorectal cancer metastasis to the liver.  J Am Coll Surg 2004; 199(3S):81.
    40. Umetani N, Shinozaki M, Fujimoto A, Takeuchi H, Bilchik AJ, Hoon DS.  Allelic loss at the APAF-1 locus facilitates colorectal carcinogenesis and metastasis to the liver.  Proc Am Assoc Cancer Res 2004;45:764-765.
    41. Saha S, Dan AG, Bilchik AJ, Beutler T, Doan K, AlSamkari R, Wiese D, Turner R, Barber K.  Mechanisms of failure and skip metastasis in sentinel lymph node mapping for colorectal cancer.  Ann Surg Oncol 2005;12(2):S83.
    42. Martinez SR, Kuo CT, Bilchik AJ, Kim J, Morton DL, Hoon DSB.  Downregulation of tumor suppressor Runx genes in malignant cutaneous melanoma.  J Clin Oncol 2005; 23:717S.
Invited Participant, Lectureships and Presentations:

1st International Workshop on Neuroimmunomodulation

1990 Presented
The Neuroimmunomodulatory role of cholecystokinin.
1st Multidisciplinary Colorectal Cancer Congress
2001 Presented
Local Treatment of liver metastases.
10th World Congress of Cryosurgery
1998 Presented
A 5-year institutional experience with hepatic cryosurgery for unresectable
colorectal metastases refractory to chemotherapy.
1998 Presented
An alternative strategy in the treatment of patients with unresectable
hepatomas.

23rd annual Gary Wratten Surgical Symposium

2001 Senior Author - Presentation
Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study.

38th World Congress of Surgery

1999 Presented
Prognostic factors and the role of chemotherapy in 153 patients undergoing
cryosurgery for unresectable colorectal metastasis.

American Association of Endocrine Surgeons

1989 Presented
H2 receptor blockade induction peptide YY (PYY) and enteroglucagon (EG)
secreting gastric carcinoids in mastomys.
1994

Presented
Peptide YY immunoneutralizaton inhibits meal induced absorption in vivo.

1997 Presented
Cryosurgical palliation of metastatic neuroendocrine tumors resistant to
conventional therapy.
2001 Senior Author - Presentation
Hepatic cytoreduction followed by a novel long-acting somatostatin analogue: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
American Cancer Society’s 41st Science Writers Seminar
1999 Presented
Universal application of the sentinel node technique in solid cancers.
American College of Surgeons, Clinical Congress
1998

Presented
Detection of pancreatic carcinoma with a novel multi-marker RT-PCR assay.

1998 Presented
Gangliosides as potential immunotherapy targets in pancreatic cancer.
2000 Invited Lecturer
Evolving techniques for treatment of metastatic tumors.
2001 Invited Lecturer
Vaccine Immunotherapy with CancerVax in Advanced Colon Cancer.
2001 Invited Lecturer
Lymphatic mapping and sentinel node analysis improves staging accuracy in gastrointestinal neoplasms.
2001 Invited Discussant
Treatment of Pancreatic Pseudocyst of Percutaneous Endoscopic Cystogastrostomy.
2002 Invited Lecturer
Sentinel lymph node resection for colorectal cancer.
2003 Presented
Missed micrometastases and aberrant drainage patterns: Challenging the therapeutic equation in gastrointestinal neoplasms
2003 Invited Lecturer
Ablative techniques: RFA vs. cryosurgery
2003 Invited Lecturer
Sentinel node discussion for G.I. malignancies
2004 Invited Lecturer
Ablative techniques for metastatic malignancies: minimally invasive but should they replace resection?
2004 Invited Lecturer
Lymphatic Mapping in Gastrointestinal Neoplasms: Challenging the Therapeutic Equation
2004 Contributing Author
CXCR4 chemokine receptor mediates melanoma and colorectal cancer metastasis to the liver.
2004 Invited Lecturer
Complications of Radiofrequency Ablation: When to use it and when not to?
2005 Invited Lecturer
Lymphatic Mapping in Gastrointestinal Neoplasms: Challenging the Therapeutic Equation
2006 Invited Lecturer
Integration of New Ablation Technologies with Hepatic Resection and Systemic Therapy
2006 Invited Lecturer
Lymphatic Mapping in Gastrointestinal Neoplasms
American College of Surgeons Oncology Group
1999-2001 Invited Participant / Co-Investigator
Lymph node mapping and sentinel lymph node biopsy for stage I, II, III colon
cancer.
American College of Surgeons, Northern California Chapter
2003 Invited Lecturer
Radioguided surgery: Technologic advance or marketing gimmick!
American College of Surgeons, Southern California Chapter
1999 Senior Author – Presentation
Radiofrequency ablation – A novel primary and adjunctive technique for hepatic
malignancies.
2000 Senior Author – Presentation
Focused examination of sentinel lymph nodes upstages early colorectal
carcinoma.
2001 Senior Author - Presentation     
A novel lymphatic mapping technique to improve cancer staging during laparoscopic colectomy.
2003 Contributing Author – Poster Presentation
Chronic management of recurrent hepatic tumors using sequential radiofrequency ablation.
2003 Senior Author – Presentation
Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: Impact on adjuvant treatment.
2006 Senior Author – Poster Presentation
Radiofrequency ablation for hepatic metastases: do the newer probes decrease recurrence?
2006 Senior Author – Presentation
Treatment disparities in Hispanic rectal cancer patients: a SEER database study.
2007 Invited Lecturer
Treatment of Colorectal Liver Metastases. What are the limits? What are the goals?
2008 Senior Author – Presentation
Treatment patterns for micrometastases of colon cancer.
American College of Surgeons Surgical Forum
2001 Contributing Author - Presentation
Targeting ceramide metabolism – A novel strategy for colon cancer therapy.
American Gastroenterological Association
1988 Presented
Amelioration of traumatic pancreatitis by CCK receptor antagonists.
1988 Presented
Is cholecystokinin an essential pancreatic growth factor?
1993 Presented
Physiological significance of PYY in small intestinal absorption in vivo.
1993 Presented
Na+/H+ exchange regulates postprandial ileal absorption.
2000 Presented
Molecular staging of colon cancer using a novel approach: A multi-center
phase II trial.
2004 Invited Lecturer
Laparoscopic Lymphatic Mapping: “Challenging the Therapeutic Equation in Colon Cancer”
2005 Contributing Author – Poster Presentation
MAGE-A3 expression correlates with disease outcome in pancreatic cancer.
2006 Contributing Author – Poster Presentation
Epigenetic inactivation of WNT inhibitory factor-1 gene promotes colorectal tumorigenesis.

American Hepato Pancreato Biliary Association

2005

Invited Lecturer
Laparoscopic Radiofrequency Ablation

American Radium Society

1998

Poster presentation
An alternative strategy in the treatment of patients with unresectable hepatomas.

1998

Presented
Universal application of intraoperative lymphatic mapping and sentinel
lymphadenectomy in solid neoplasms.

1998

Presented
Cryosurgery of hepatocellular carcinoma.

1999

Presented
Radiofrequency ablation – a novel, minimally invasive technique with multiple
applications. 

2001 Senior Author –Presentation
TA90-IC and Anti-GM2 IgM response: novel immunologic markers in colorectal cancer and predictors of survival.

American Society of Clinical Oncology

1997

Presented
Cryoablation of primary and metastatic liver cancer unresponsive to
conventional therapy.

1999

Poster Presentation
Systemic irinotecan (CPT-11) and regional chemotherapy prolong survival after
hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-
fluorouracil (5-FU).

1999

Published Abstract
Polyvalent vaccine induces an immune response to carbohydrate antigens in
stage IV colon cancer.

2000

Poster Presentation
Molecular staging of early colon cancer: Lymphatic mapping and sentinel
node analysis for occult micrometastases.

2001

Invited Lecturer
Sentinel node technique for staging and treatment decisions.

2001

Presented
CancerVax, a polyvalent vaccine improves survival in refractory stage IV colon       cancer: A phase II trial.

2002

Poster Presentation
Multivariate analysis of 18 prognostic factors in early colorectal cancer: a prospective multicenter trial.

2003

Invited Lecturer
Thermal ablation of hepatic colorectal metastasis: Should this minimally invasive technique replace resection?

2003

Invited Lecturer
The impact of lymphatic mapping and sentinel lymph node analysis on gastrointestinal neoplasms.

2005

Invited Lecturer
Therapeutic options for unresectable hepatic metastases: What are the limits?  What are the goals?

2006 Invited Lecturer
Integration of New Ablation Technologies with Hepatic Resection and Systemic Therapy

American Society of Clinical Oncology-Gastrointestinal Cancers Symposium

2006

Senior Author- Presentation (Poster)
A comparison of oxaliplatin-based adjuvant chemotherapy versus improved nodal sampling for stage II colon cancer: cost-effectiveness and survival

American Surgical Association
2002 Co-Author – Oral Presentation
Long-term results of lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma:  Implications of nodal microanatomy and molecular staging on detection of nodal micrometastases.
2006

Senior Author-Oral Presentation
Does more extensive nodal dissection improve survival for resectable colon cancer? A population based study.

2007

Presented
Prognostic Impact of Micrometastases in Colon Cancer: Interim Results of a Prospective Multicenter Trial.

Association of Academic Surgeons

1989

Presented
Continuous cholecystokinin receptor blockade in newborn guinea pigs
impaired growth and altered secretagogue response.

1989

Presented
Manipulation of subcellular pH during experimental acute pancreatitis.

1993

Presented
A unique hormonal mediator of intestinal glucose transport and paracellular
permeability.

1993

Presented
Adaptation of Na+/glucose co-transporter following intestinal resection.

1993 Presented
Mechanisms of EG synthesis and release after massive small bowel resection.

Association of Veterans Administration Surgeons

1989

Presented
Peptide YY release from short chain fatty acids: Evidence of human colonic
evolution?

1990 Presented
Amelioration of cholinergic induced pancreatitis with a selective
cholecystokinin receptor antagonist.

Boerhaave Professorship

2001

Visiting Professor, University of Leiden, Netherlands
Colorectal Cancer.

Brooklyn Surgical Society

2008

Visiting Professor, Lymph nodes: More than a staging operation in early colon cancer?

Carcinoid Fighters
2002-2006 Invited Lecturer
Aggressive cytoreduction improves symptoms in patients with refractory neuroendocrine tumors.
Cedars Sinai Grand Rounds
2004

Invited Lecturer
Missed Micrometastases and Aberrant Drainage Patterns:  Challenging the Therapeutic Equation in Gastrointestinal Neoplasms.

2009 Invited Lecturer
Advances in the Management of Colorectal Hepatic Metastases: A Multidisciplinary Approach.

Cell Biology

1989

Presented
PYY, SRIF, PP and EG colocalization in the rodent pancreas.

A Century of Advances in Neuroendocrine Tumors-A Tribute to Siegfried Oberndofer

2007

Invited Lecturer
Current and Emerging Strategies for the Treatment of Unresectable Hepatic Neuroendocrine Metastases

Circulating Nuclei Acids in Plasma and Serum

2005

Contributing Author – Poster presentation
Detection of gastrointestinal cancers by free circulating DNA integrity in serum using quantitative PCR.

Colon and Rectal Cancers-New Approaches to Assessing and Treating Early Stage Colon and Rectal Cancers

2007 Invited Lecturer
Surgeon or the Pathologist as a prognostic factor in Colorectal Cancer

Connecticut Chapter of the American College of Surgeons

1988

Presented
1st prize awarded cancer competition 1988
Rapid carcinoid tumor induction in mastomys with H2 receptor blockage.

Creighton University Department of Biomedical Sciences

1989

Visiting Lecturer
Investigation into biochemistry and pathophysiology of a novel gastric
endocrine tumor model.

CURE/UCLA

1993

Presented
Role of Na+/glucose co-transporter in meal-induced proabsorption.

Current Trends in Colorectal Cancer Series

2005

Invited Lecturer
Thermal Ablation of Hepatic Colorectal Metastases.

Downstate University

2008

Grand Rounds: Hepatectomy for colorectal liver metastases: What are the limits, what are the goals?

Federation of American Experimental Societies for Biology

1988

Presented
CCK receptor blockade increases hamster body weight and food intake.

Harbor-UCLA Medical Center

2003

Invited Lecturer – Surgery Grand Rounds
Radiofrequency ablation of hepatic colorectal metastases: Minimally invasive, but should it replace resection?

Hoag Hospital

2007

Invited Lecture-Grand Rounds
Treatment of Colorectal Liver Metastases What are the limits? What are the goals?

International Conference on Gastroenteric Biology

1988

Presented
A novel micro-method for pancreatic acinar secretion: Time course of CCK
stimulation and its inhibition by L364, 718.

International Sentinel Node Congress

2000 Presented
Lymphatic mapping and focused analysis of the sentinel lymph node upstages gastrointestinal neoplasms.
2002

Invited Lecturer
The impact of lymphatic mapping and sentinel node analysis on the new staging system for colon cancer.

2004

Contributing Author – Oral presentation
A comparison of various tracers for lymphatic mapping for colorectal cancer.

2004

Invited Lecturer
Current Status and Future Colon Sentinel Node Surgery

2004

Invited Lecturer
Meet the professors- GI Cancers Breakfast

2004

Contributing Author – Poster presentation
Comparative analysis of nodal metastasis for T3 and T4 colon cancer between sentinel lymph node mapping vs. conventional surgery. 

McLaren Regional Medical Center

1999 Visiting Lecturer
8th Annual “Advances in Cancer Therapy.”

MD Anderson Cancer Center

2008 Visiting Lecturer
Resecting Lymph Nodes In Colon Cancer: More than a staging operation? 

Medtronic Colorectal Cancer Symposium

2002

Presented
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases.

National Cancer Institute, Organ Systems Branch

1999

Participant
“Pancreatic Cancer Think Tank.” 

National Gut Hormone Symposium

1988

Presented
CCK and a new surgical model of pancreatitis.

New England Society of Colon and Rectal Surgeons

1989

Presented.
Release of peptide YY in humans.

Oncology:Clinical Issues and Trends

2006 Invited Lecturer
Advances in the Surgical Management of Colorectal Hepatic Metastases

Pacific Coast Surgical Association

2000

Senior Author – Presentation
Lymphatic mapping and focused analysis of sentinel lymph nodes upstages
gastrointestinal neoplasms.

2002

Senior Author - Presentation
Anti-GM2 IgM response is the only predictor of survival in stage II colorectal cancer.

2007 Senior Author-Presentation
Angiogenesis markers in early colorectal cancer predict lymph node metastases.

Pancreas Club

1988

Presented – Digestive Disease Week
CCK receptor blockade in two models of experimental pancreatitis not mediated
via CCK receptors.

2005

Contributing Author – Oral presentation
Detection of KRAS DNA mutation in the surgical margins of resected pancreatic adenocarcinoma correlates with survival.

Roswell Park Cancer Center, Grand Rounds

2005

Invited Lecturer
Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation

San Diego Society of General Surgeons

2003

Invited Lecturer

Impact of lymphatic mapping and sentinel lymph node analysis on the new TNM staging.
Society of American GI Endoscopic Surgeons (SAGES)
2000 Senior Author – Presentation
Diagnostic laparoscopy and laparoscopic ultrasonography optimize staging and
resectability of intra-abdominal tumors.
2000 Senior Author - Presentation
Laparoscopic ultrasound and radiofrequency ablation of nonresectable hepatic
malignancies: A phase II trial.
2000 Senior Author - Presentation
Colonoscopic lymphatic mapping in laparoscopic colectomy for cancer.
2000 Faculty Lecturer – Postgraduate Course I
Sentinel node technique for colorectal neoplasms.

Society for Surgery of Alimentary Tract

1988 >Presented-Digestive Disease Week<
Does VIP mediate the pathophysiology of bowel obstruction?
1993

Presented
PYY augments postprandial small intestinal absorption in vivo.

1997

Presented
Human pancreatic carcinoma growth and invasion is regulated by C-MET and
interleukin 4 receptor gene expression.

2000

Senior Author – Poster Presentation
Repeat hepatic cryotherapy for metastatic colorectal cancer.

2001

Senior Author - Poster Presentation
Diagnostic laparoscopy and laparoscopic ultrasonography are essential for staging intraabdominal neoplasms.

2001

Senior Author - Presentation
One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases.

2002

Senior Author - Presentation
Lymphatic mapping combining blue dye with intraoperative lymphoscintigraphy improves detection of micrometastases in early colorectal cancer.

2002 Second Author - Presentation
Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy.

Society of Surgical Oncology

1997

Senior Author – Presentation
Radiofrequency ablation of 231 unresectable hepatic tumors: indications,
limitations & complications.

1997

Presented
Cryosurgery ameliorates unresectable hepatic neuroendocrine metastases.

1998

Presented
Cellular immune response to CancerVax in patients receiving active
immunotherapy for metastatic cancers.

1998

Poster Presentation
Survival and the humoral immune response to TA90 in patients receiving active
immunotherapy with CancerVax for metastatic cancers.

1998

Presented
Do all patients with sentinel node metastasis from breast carcinoma need
complete axillary node dissection?

1999 Presented
Survival is correlated with humoral response to TA-90 in patients receiving
CancerVax for metastatic cancers.
1999

Poster Presentation
Radiofrequency ablation and intraoperative ultrasound – a novel approach for
management of unresectable hepatic malignancies.

1999 Poster Presentation
TA-90 – A new marker for colon cancer.
2000

Senior Author-Poster Presentation
Designing a strategy for the care of children with melanoma.

2000

Senior Author – Presentation
Validation of lymphatic mapping in colorectal carcinoma: In-vivo, ex-vivo and
laparoscopic techniques.

2000

Senior Author – Presentation
Radiofrequency ablation of 174 unresectable hepatic tumors: indications,
limitations and complications.

2000

Invited Presenter
RT-PCR techniques to detect micrometastases in lymph nodes.

2000

2nd Author – Presentation
Accuracy of ultrastaging of colorectal cancer by exclusive examination of
sentinel lymph nodes: A prospective study.

2001

Senior Author – Poster Presentation
Cryosurgical ablation of hepatic colorectal carcinoma metastases induces autoimmunization with tumor specific antibodies.

2001

Senior Author - Presentation

Improved survival in refractory stage IV colorectal cancer is associated with a specific immune response to TA90.
2001

Senior Author - Presentation
The results of hepatic cytoreduction plus regional and systemic chemotherapy in 185 patients with unresectable colorectal cancer metastasis.

2002

Co-Author - Presentation
Modulators of ceramide metabolism enhance irinotecan-mediated apoptosis of colon cancer cells by a p53-independent process.

2002

Senior Author - Presentation
Radiofrequency ablation in 406 complex unresectable liver tumors: Lessons learned.

2002

Panelist - Contemporary Surgery Symposium
Ablative therapies for liver cancer.

2002

Presented – “Meet the Professor” Breakfast
Sentinel lymph node biopsy and colon cancer: Breakthrough vs. fad.

2003

Presented – “Meet the Professor” Breakfast
Micrometastases in colon cancer: Perception vs. reality.

2003

Invited Lecturer
Tailoring treatment to improve survival in hepatic colorectal metastases.

2005 Presented – “Meet the Professor” Breakfast
Ablation of Liver Metastasis, Minimally Invasive but Should It Replace Resection?
2006 Invited Lecturer
Indications and Evidence for Radiofrequency Ablation of Liver Tumors
2007

Invited Lecturer
Treatment of Colorectal Liver Metastases What are the limits? What are the goals?

Society of University Surgeons

1993

Presented
Effects of luminal hexoses on jejunal absorption.

Southern California Society of Colon and Rectal Surgeons

2005 Invited Lecturer
Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation

Southwestern Surgical Congress

2007

Senior Author-Oral Presentation
Management of T2 Gallbladder Cancer: Are Practice Patterns Consistent With National Recomendations

Surgical Forum

1989

Presented
cAMP mediated release of PYY from the isolated perfused colon: Evidence for
negative feedback modulation of colonic secretion.

1993

Presented
PYY gene expression is an early adaptive response to massive small bowel
resection.

1993

Presented
Translational control of meal-induced absorption.

Tripartite Surgical Meeting

1988

Presented
New specific CCK receptor antagonist ameliorates surgically induced
pancreatitis both pre and post insult.

University of California Irvine Grand Rounds

2005

Invited Lecturer
Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation

University of California Los Angeles

1997

Visiting Lecturer
Physiology and bioactivity of gastrointestinal hormones.

University of California San Francisco-  International Symposium on Cancer Metastasis and the Lymphovascular System

2005

Invited Lecturer
Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation

2007 Invited Lecturer
GI cancer and the lymphatic system: Patterns of micrometastasis and lymphatic mapping with clinical outcome
2007 Senior Author-Poster Presentation
Thrombospondin; protective in preventing lymphatic metastases in colon cancer.

University of Minnesota

1998 Participant
Hepatic, Biliary & Pancreatic Surgery.

University of Nebraska

1997

Visiting Lecturer
Management of unresectable liver tumors.

University of Southern California Grand Rounds

2004

Invited Lecturer
Challenging the therapeutic equation in gastrointestinal tumors

University of Sydney

1998 Visiting Lecturer - Graham Coupland Lecture
Universal application of lymphatic mapping and sentinel node biopsy in solid
neoplasms.
University of the Witwatersrand Medical Grand Rounds
1987

Visiting Lecturer
Potential therapeutic role of CCK receptor antagonists in pancreatic disease.

University of Cape Town Department of Chemical Pathology

1987 Visiting Lecturer
Role of CCK in the pathogenesis of acute pancreatitis. 

Valley Lab Cool-Tip Liver RFA Symposium – Denver

2004

Invited Lecturer
Thermal Ablation of Hepatic Colorectal Metastases

Valley Lab Cool-Tip Liver RFA Symposium – La Jolla
2005

Invited Lecturer
Thermal Ablation of Hepatic Colorectal Metastases

Waterford Surgical Club – Waterford, Ireland

2005

Invited Lecturer
Thermal Ablation of Colorectal Liver Metastases: Minimally Invasive but Should it Replace Resection?

2005 Invited LecturerLymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation.  

West Hawaii Cancer Symposium

2001

Invited Lecturer

Local/Regional approaches for hepatic tumors –What are the indications?
2001

Invited Lecturer
Resected rectal cancer – Is adjuvant therapy still appropriate?

2002

Invited Lecturer
Advanced colon cancer: Is cure possible?

2002

Invited Lecturer
Adjuvant and palliative treatment of hepatic colorectal metastases: Integrating therapeutic options.         

Western Surgical Association

1999 Presented
Cryosurgery and radiofrequency ablation of unresectable hepatic malignancies:
A proposed algorithm.
2001

Presented
Molecular profiling of early colon cancer predicts micrometastases.

2004

Discussant
GIST tumors express RAS oncogene: A potential role for diagnosis and treatment.

2005

Oral Presentation
Prospective multicenter trial of staging adequacy in colon cancer: Preliminary results.

2005

Senior Author – Oral presentation
Long term survival with 521 complex unresectable liver tumors after radiofrequency ablation.

2006

Senior Author-Oral Presentation
The Role of Repeat Hepatectomy in the Mulitmodal Treatment of Hepatic Colorectal Metastases

World Congress of International Society for Digestive Surgery

2004 Invited Lecturer
Dual-agent mapping of the sentinel node in colorectal cancer
2004

Invited Lecturer
Navigating the sentinel node technique across cancers and continents

World Congress of Surgery

1999

Presented
Prognostic factors and the role of chemotherapy in 153 patients undergoing cryosurgery for unresectable colorectal metastases. 

   
Copyright © 2013 Corigroup.org. All Right Reserved.